

Special Issue

Medical Treatment for Urological Cancers

Message from the Guest Editor

The past decade has been characterized by the advent of new therapeutic modalities for the medical treatment of prostate, urothelial and renal cancers. Classic and novel androgen deprivation therapy, cytotoxic chemotherapy, immune checkpoint inhibitors, tyrosine kinase inhibitors and antibody–drug conjugates are now the standard of care for the most common urologic malignancies. Moreover, the treatment paradigm is undergoing a dramatic shift with the advent of the first targeted therapies in uro-oncology, notably PARP and FGFR inhibitors, marking a pivotal moment in the management of these diseases. This rapidly evolving landscape necessitates the reevaluation of treatment sequencing priorities, and will inevitably result in the phasing out of once-familiar substances from clinical guidelines. The objective of this Special Issue is to navigate the reader through these significant changes, offering insights into the future direction of medical treatment for urological cancers and highlighting the importance of adapting to these new therapeutic opportunities. We look forward to receiving your contributions.

Guest Editor

Dr. Jozefina Casuscelli

1. Department of Urology, University Hospital of Munich, 81377 Munich, Germany
2. Comprehensive Cancer Center, University Hospital of Munich, 81377 Munich, Germany

Deadline for manuscript submissions

30 April 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/199540

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)